Our purpose is to ensure every patient has access to ATMPs.
adthera is your partner for innovative, optimised-quality, high-technology, cell & gene therapy-focussed development and manufacturing. We have an obsession on customer needs driving our vision of access to ATMP for patients.
We take your cell therapy ideas and make them into workable medical interventions for patients, all in a regulatory compliant and quality managed system, to get it right first time. Based on brilliant ideas and curious capable minds, we partner with biotechs and academic centres to bring novel ATMP therapies to market and thus to patients who urgently need them. We have highly personalised approaches from the patient to the client to the treatment outcome.
By being constantly curious and pushing the regulations and innovations in this novel area of medicine, we aim to make a positive difference on patient’s lives.
We live by our values of Integrity, Trust & Respect, Bravery, Agility, and Passion & Commitment.
Gained with over 20 different Cell & Gene Therapy companies and academic centres and in collaboration with over 50 institutions
Autologous >600 patients
Allogenic >700 patients
As a venture-backed business we always welcome discussions with new investors. For investors, please contact Colin (our CEO) to talk more.
Reach us at the email or address below, or alternatively use the contact form and we’ll get back to you as soon as firstname.lastname@example.org
Birmingham | Lyndon House, 62 Hagley Rd, Birmingham B16 8PE
London | 15 Stukeley Street, London WC2B 5LT